How Many ValiRx Plc (LON:VAL)’s Analysts Are Bearish?

November 21, 2017 - By Marie Mckinney

 How Many ValiRx Plc (LON:VAL)'s Analysts Are Bearish?
Investors sentiment decreased to 0.01 in 2017 Q2. Its down 0.91, from 0.92 in 2017Q1. It fall, as 283 investors sold ValiRx Plc shares while 1 reduced holdings. 0 funds opened positions while 2 raised stakes. 1.24 million shares or 97.61% less from 51.76 million shares in 2017Q1 were reported.
601 are held by Glenmede Na. Bahl & Gaynor accumulated 23,066 shares. Pictet Asset Mgmt holds 0.01% or 26,000 shares. Envestnet Asset Mgmt Inc owns 756 shares. Alpine Associate Management reported 1.19 million shares.

ValiRx Plc (LON:VAL) Ratings Coverage

Among 2 analysts covering ValiRx PLC (LON:VAL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ValiRx PLC had 40 analyst reports since September 16, 2015 according to SRatingsIntel. The stock has “Corporate” rating by Northland Capital on Thursday, December 8. Beaufort Securities maintained the stock with “Speculative Buy” rating in Friday, October 13 report. Beaufort Securities maintained it with “Speculative Buy” rating and GBX 6.50 target in Friday, June 16 report. The firm earned “Corporate” rating on Thursday, November 3 by Northland Capital. The stock of ValiRx Plc (LON:VAL) has “Corporate” rating given on Thursday, August 11 by Northland Capital. Beaufort Securities maintained the stock with “Speculative Buy” rating in Thursday, January 12 report. The rating was maintained by Beaufort Securities on Monday, July 31 with “Speculative Buy”. On Tuesday, June 7 the stock rating was maintained by Northland Capital with “Corporate”. The firm earned “Corporate” rating on Thursday, July 28 by Northland Capital. The rating was maintained by Northland Capital with “Corporate” on Thursday, May 19. Below is a list of ValiRx Plc (LON:VAL) latest ratings and price target changes.

16/11/2017 Broker: Beaufort Securities Rating: Speculative Buy Old Target: GBX 6.50 New Target: GBX 6.50 Maintain
13/10/2017 Broker: Beaufort Securities Rating: Speculative Buy Old Target: GBX 6.50 New Target: GBX 6.50 Maintain
29/09/2017 Broker: Beaufort Securities Rating: Speculative Buy Old Target: GBX 6.50 New Target: GBX 6.50 Maintain
27/09/2017 Broker: Beaufort Securities Rating: Speculative Buy Old Target: GBX 6.50 New Target: GBX 6.50 Maintain
08/09/2017 Broker: Beaufort Securities Rating: Speculative Buy Old Target: GBX 6.50 New Target: GBX 6.50 Maintain
31/07/2017 Broker: Beaufort Securities Rating: Speculative Buy Old Target: GBX 6.50 New Target: GBX 6.50 Maintain
16/06/2017 Broker: Beaufort Securities Rating: Speculative Buy Old Target: GBX 6.50 New Target: GBX 6.50 Maintain
25/05/2017 Broker: Beaufort Securities Rating: Speculative Buy Old Target: GBX 6.50 New Target: GBX 6.50 Maintain

About 869,185 shares traded. ValiRx Plc (LON:VAL) has 0.00% since November 21, 2016 and is . It has underperformed by 16.70% the S&P500.

ValiRx plc is a biopharmaceutical company. The company has market cap of 909,677 GBP. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It currently has negative earnings. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.